Advertisement

Chronic Myeloid Leukemia: Long-Term Outcome Data in the Imatinib Era

  • Prasanth GanesanEmail author
  • Trivadi S. Ganesan
  • Venkatraman Radhakrishnan
  • Tenali Gnana Sagar
  • Krishnarathinam Kannan
  • Manikandan Dhanushkodi
  • Jayachandran Perumal Kalayarasi
  • Nikita Mehra
Original Article
  • 20 Downloads

Abstract

Recent reports suggest that in the TKI era, the survival of chronic myeloid leukemia approaches that of general population. The real-world situation may be different. We analyzed patients (≥ 18 years) with chronic phase (CP) CML enrolled over a 7-year period (2002–2008) in an imatinib access program. Event was defined as non-achievement/loss of complete hematological response (CHR), loss of cytogenetic response or progression to accelerated (AP)/blast phase (BC). Progression was defined as development of AP/BC. Any delay of ≥ 1 week in reporting for drug refills was categorized as non-adherence. Of the 443 patients with CP-CML who started imatinib [median age: 36 years (18–70); High risk: 32% (Sokal) and 14% (Hasford/EUTOS)], 162 (37%) had received prior therapy [mostly hydroxyurea (N = 153]. CHR was achieved by 430 (97%). After a median follow up of 109.5 months (3.4–184.3), the EFS, PFS and OS at 10 years was 43%, 75% and 76% respectively. Superior EFS was predicted by low-risk Hasford score and adherence to therapy. Adherence to therapy was the only factor which predicted EFS on multivariate analysis (HR 0.64, 95% CI 0.50–0.83, P = 0.001). Long-term follow up of patients with CP-CML reflects poorer survival than those reported from clinical trials and reflects multiple issues that affect “real-world” patients. The continued drop in EFS, noted during long-term follow up, might take time to impact the PFS and OS due to the chronic nature of the disease. Sustained adherence to therapy is important for optimum long-term outcomes.

Keywords

Chronic myeloid leukemia Imatinib Long-term outcomes 10-Year survival Adherence 

Notes

Acknowledgements

We acknowledge the support from the Glivec International Patient Assistance Program and the Tamilnadu Government Insurance Scheme for supporting the medication for the patients. We thank Ms Tamilselvarani and Ms Vanitha N for helping patient coordination and data collection.

Author Contribution

Conceptualization, data curation, investigation: all authors. Manuscript writing: PG, NM, JPK, TSG. Supervision and resources: PG, TGS.

Funding

The study was supported by Cancer Institute (WIA) funds. No grant number is applicable.

Compliance with Ethical Standards

Conflict of interest

None of the authors have any relevant conflicts of interests to declare.

References

  1. 1.
    Ganesan P, Kumar L (2017) Chronic myeloid leukemia in India. J Glob Oncol 3(1):64–71CrossRefGoogle Scholar
  2. 2.
    Goldman JM (2013) Chronic myeloid leukemia in India. Indian J Med Paediatr Oncol 34(3):147–148CrossRefGoogle Scholar
  3. 3.
    Glivec® International Patient Assistance Program (GIPAP). http://www.themaxfoundation.org/gipap/Default.aspx. Accessed 31 Mar 2018
  4. 4.
    Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F et al (2015) Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 29(9):1823–1831CrossRefGoogle Scholar
  5. 5.
    Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851–2857CrossRefGoogle Scholar
  6. 6.
    Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917–927CrossRefGoogle Scholar
  7. 7.
    Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30(1):48–56CrossRefGoogle Scholar
  8. 8.
    Flynn KE, Atallah E (2016) Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep 11(2):80–85CrossRefGoogle Scholar
  9. 9.
    Perry AM, Brunner AM, Zou T, McGregor KL, Amrein PC, Hobbs GS et al (2017) Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: a population-based study. Cancer 123(13):2561–2569CrossRefGoogle Scholar
  10. 10.
    Pulte D, Barnes B, Jansen L, Eisemann N, Emrich K, Gondos A et al (2013) Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. J Hematol Oncol 6(1):70CrossRefGoogle Scholar
  11. 11.
    Pulte D, Jansen L (2017) Population-level survival for patients with chronic myeloid leukemia: higher survival in Sweden than internationally. J Clin Oncol 35(6):695–696CrossRefGoogle Scholar
  12. 12.
    Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S et al (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86(6):471–474CrossRefGoogle Scholar
  13. 13.
    Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850–858CrossRefGoogle Scholar
  14. 14.
    Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041–6051CrossRefGoogle Scholar
  15. 15.
    Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63(4):789–799Google Scholar
  16. 16.
    Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ et al (2017) Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31(11):2398–2406CrossRefGoogle Scholar
  17. 17.
    Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981–1987CrossRefGoogle Scholar
  18. 18.
    Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP et al (2017) Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival. Haematologica 102(12):e486–e489CrossRefGoogle Scholar
  19. 19.
    Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B (2014) Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 99(3):437–447CrossRefGoogle Scholar
  20. 20.
    Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388CrossRefGoogle Scholar
  21. 21.
    Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP et al (2017) Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia. Haematologica 102(11):1842–1849CrossRefGoogle Scholar
  22. 22.
    Unnikrishnan R, Veeraiah S, Mani S, Rajendranath R, Rajaraman S, Vidhubala Elangovan GS et al (2016) Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib. Clin Lymphoma Myeloma Leuk 16:366–371CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  • Prasanth Ganesan
    • 1
    Email author
  • Trivadi S. Ganesan
    • 1
  • Venkatraman Radhakrishnan
    • 1
  • Tenali Gnana Sagar
    • 1
  • Krishnarathinam Kannan
    • 1
  • Manikandan Dhanushkodi
    • 1
  • Jayachandran Perumal Kalayarasi
    • 1
  • Nikita Mehra
    • 1
  1. 1.Department of Medical OncologyCancer InstituteChennaiIndia

Personalised recommendations